^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AVE9633

    i
    Other names: AVE9633, AVE 9633, huMy9-6-DM4, huMY96DM4
    Associations

    News

    Trials
    Company:
    AbbVie, Sanofi
    Drug class:
    Microtubule inhibitor, CD33-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    over3years
    CD33-Targeted Therapies: Beating the Disease or Beaten to Death? (PubMed, J Clin Pharmacol)
    Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML...Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit.
    Review • Journal
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • IMGN779 • vadastuximab talirine (SGN-CD33A) • vixtimotamab (AMV564) • AVE9633 • GTB-3550 TRIKE • eluvixtamab (AMG 330)